Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Ovarian Cancer Identification on CT Using Deep Learning

NCT06851429 · tracked via the Priya Life Science Taiwan tracker
Phase
Observational
Started
2022-09-01
Last updated
2026-08-12

Condition(s) studied

Ovarian Cancer

Study summary

Ovarian cancer remains the deadliest gynecologic malignancy, with poor survival rates largely due to late-stage diagnosis. Early detection is crucial, yet no universally accepted screening method exists. Current imaging techniques and biomarkers, such as CA-125, have limitations in specificity and sensitivity. This study aims to develop and evaluate a deep learning-based computer-aided diagnosis tool (CAT-OV), for ovarian cancer detection using CT imaging. The system integrates a Body Part Regression (BPR) model for pelvic localization and a Multiple Instance Learning (MIL) ensemble classifier for cancer prediction. The model was trained and validated using retrospective datasets from Taiwan, the United States, and a nationwide real-world cohort. Stringent preprocessing and quality control measures were implemented to enhance model accuracy. Results highlight the potential of AI-driven CT screening in improving early detection, though further validation is needed for clinical adoption.

Eligibility

Sex
FEMALE
Min age
20 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: 1. Age ≥ 20 years old. 2. Female 3. undergone a CT scan 4. undergone a CT scan within 180 days prior to ovarian surgery for histopathological evaluation. Exclusion Criteria: 1. Age \< 20 years old. 2. Non-female 3. Non-CT imaging 4. Incorrect image orientation 5. Number of slices \< 10 6. Slice thickness \>10 mm or \< 1 mm 7. Unsuccessful DICM-to-NIfTI 8. Pelvic subvolume extraction failed 9. Non-contrast CT scans 10. Metallic artifacts 11. Inconclusive cases

Primary outcome measure(s)

  • Performance of a deep learning-based computer-aided diagnosis tool (CAT-OV) for identification of primary ovarian cancer on CT — Perioperative/Periprocedural 180 days
    Sensitivity, Specificity, Accuracy, PPV, NPV, AUC

Trial sites (2)

FacilityCityRegionStatus
Chang Gung Memorial Hospital Taoyuan City Guishan District Completed
Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital Taoyuan Guishan Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06851429 on ClinicalTrials.gov ↗ ← All trials in Taiwan